Beam Therapeutics (BEAM) Income towards Parent Company (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Income towards Parent Company data on file, last reported at -$97.3 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$97.3 million, up 11.03% year-over-year; the trailing twelve-month figure through Mar 2026 was -$68.1 million (up 82.43% YoY), and the FY2025 annual result was -$80.0 million, up 78.77% from the prior year.
• Income towards Parent Company slipped to -$97.3 million in Q1 2026 per BEAM's latest filing, from $244.3 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $244.3 million in Q4 2025 and troughed at -$112.7 million in Q3 2025.
• A 5-year average of -$55.9 million and a median of -$90.4 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2023: Income towards Parent Company slumped 199.01% in 2022, then soared 472.18% in 2023.
• A 5-year view of Income towards Parent Company shows it stood at -$38.4 million in 2022, then soared by 472.18% to $142.8 million in 2023, then plunged by 163.29% to -$90.4 million in 2024, then surged by 370.38% to $244.3 million in 2025, then plunged by 139.85% to -$97.3 million in 2026.
• Business Quant data shows BEAM's Income towards Parent Company at -$97.3 million in Q1 2026, $244.3 million in Q4 2025, and -$112.7 million in Q3 2025.